Elixiron Immunotherapeutics attracts $27m

Elixiron Immunotherapeutics Inc, a developer of therapeutics for cancer, neurological diseases and inflammatory disorders, has closed its Series A-1 funding round at $27 million.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this